Last reviewed · How we verify

Norbert Avril, M.D. — Portfolio Competitive Intelligence Brief

Norbert Avril, M.D. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
[Ga-68]PSMA [Ga-68]PSMA marketed PET imaging agent / radiopharmaceutical PSMA (prostate-specific membrane antigen) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. HTA Co., Ltd. · 1 shared drug class
  3. Hackensack Meridian Health · 1 shared drug class
  4. Weill Medical College of Cornell University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Norbert Avril, M.D.:

Cite this brief

Drug Landscape (2026). Norbert Avril, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/norbert-avril-m-d. Accessed 2026-06-09.

Related